Evidence map›Paper›PMID 35081505›Full record

ArticleEuropean journal of cancer (Oxford, England : 1990)2022

Differences in treatment and survival of older patients with operable breast cancer between the United Kingdom and the Netherlands - A comparison of two national prospective longitudinal multi-centre cohort studies.

Willeke G van der Plas-Krijgsman, Jenna L Morgan, Nienke A de Glas, Anna Z de Boer, Charlene L Martin, Geoffrey R Holmes, Susan E Ward, Tim Chater, Malcolm W Reed, Jos W S Merkus and 10 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of cancer (Oxford, England : 1990), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Geographic variation in surgery rates among older patients with early (ER positive HER2 negative) breast cancer: Influence of cardiovascular disease and comorbidities: A national registry dataset analysis.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 11 institutions in 2 countries.

Willeke G van der Plas-KrijgsmanDepartment of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands.
Jenna L MorganDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, UK. Electronic address: j.morgan@sheffield.ac.uk.
Nienke A de GlasDepartment of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands.
Anna Z de BoerDepartment of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands; Department of Surgery, Leiden University Medical Centre, Leiden, the Netherlands.
Charlene L MartinDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Geoffrey R HolmesSchool of Health and Related Research, University of Sheffield, Sheffield, UK.
Susan E WardSchool of Health and Related Research, University of Sheffield, Sheffield, UK.
Tim ChaterSchool of Health and Related Research, University of Sheffield, Sheffield, UK.
Malcolm W ReedBrighton and Sussex Medical School, University of Brighton, Brighton, UK.
Jos W S MerkusDepartment of Surgery, Haga Ziekenhuis, The Hague, the Netherlands.
Thijs van DalenDepartment of Surgery, Diakonessenhuis, Utrecht, the Netherlands.
Annelie J E VulinkDepartment of Medical Oncology, Reinier de Graaf Gasthuis, Delft, the Netherlands.
Leander van GervenDepartment of Medical Oncology, LangeLand Ziekenhuis, Zoetermeer, the Netherlands.
Onno R GuicheritDepartment of Surgery, Haaglanden Medical Centre, The Hague, the Netherlands.
Eugenie Linthorst-NiersDepartment of Surgery, Groene Hart Ziekenhuis, Gouda, the Netherlands.
Titia E LansDepartment of Surgery, Admiraal de Ruyterziekenhuis, Goes and Vlissingen, the Netherlands.
Esther BastiaannetDepartment of Surgery, Leiden University Medical Centre, Leiden, the Netherlands.
Johanneke E A PortieljeDepartment of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands.
Gerrit Jan LiefersDepartment of Surgery, Leiden University Medical Centre, Leiden, the Netherlands.
Lynda WyldDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
University of Sheffield · GBLeiden University · NLLeiden University Medical Center · NLAdmiraal De Ruyter Ziekenhuis · NLBrighton and Sussex Medical School · GBDiakonessenhuis hospital · NLGroene Hart Ziekenhuis · NLHaga Hospital · NLLange Land Ziekenhuis · NLMedisch Centrum Haaglanden · NLReinier de Graaf Hospital · NL

Funding

Department of Health RP-PG-1209-10071
6 · The paper itself

Abstract

backgroundPrevious studies have shown that survival outcomes for older patients with breast cancer vary substantially across Europe, with worse survival reported in the United Kingdom. It has been hypothesised that these differences in survival outcomes could be related to treatment variation.

objectivesWe aimed to compare patient and tumour characteristics, treatment selection and survival outcomes between two large prospective cohorts of older patients with operable breast cancer from the United Kingdom (UK) and The Netherlands.

methodsWomen diagnosed with operable breast cancer aged ≥70 years were included. A baseline comprehensive geriatric assessment was performed in both cohorts, with data collected on age, comorbidities, cognition, nutritional and functional status. Baseline tumour characteristics and treatment type were collected. Univariable and multivariable Cox regression models were used to compare overall survival between the cohorts.

results3262 patients from the UK Age Gap cohort and 618 patients from the Dutch Climb cohort were included, with median ages of 77.0 (IQR: 72.0-81.0) and 75.0 (IQR: 72.0-81.0) years, respectively. The cohorts were generally comparable, with slight differences in rates of comorbidity and frailty. Median follow-up for overall survival was 4.1 years (IQR 2.9-5.4) in Age Gap and 4.3 years (IQR 2.9-5.5) in Climb. In Age Gap, both the rates of primary endocrine therapy and adjuvant hormonal therapy after surgery were approximately twice those in Climb (16.6% versus 7.3%, p < 0.001 for primary endocrine therapy, and 62.2% versus 38.8%, p < 0.001 for adjuvant hormonal therapy). There was no evidence of a difference in overall survival between the cohorts (adjusted HR 0.94, 95% CI 0.74-1.17, p = 0.568).

conclusionsIn contrast to previous studies, this comparison of two large national prospective longitudinal multi-centre cohort studies demonstrated comparable survival outcomes between older patients with breast cancer treated in the UK and The Netherlands, despite differences in treatment allocation.

Indexed as

Breast NeoplasmsAgedAged, 80 and overChemotherapy, AdjuvantFemaleHumansNetherlandsProspective StudiesUnited KingdomBreast cancerGeriatric oncologyOlder patientsSurvival

Identifiers

PMID35081505
PMCPMC8887607
OpenAlexW4220950685

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.